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Abstract: 343/350 words 35 
HCMV infection, reinfection or reactivation occurs in 60% of untreated solid organ transplant (SOT) 36 
recipients. Current clinical approaches to HCMV management include pre-emptive and prophylactic 37 
antiviral treatment strategies. The introduction of immune monitoring to better stratify patients at risk 38 
of viraemia and HCMV mediated disease could improve clinical management. Current approaches 39 
quantify T cell IFNγ responses specific for predominantly IE and pp65 proteins ex vivo, as a proxy 40 
for functional control of HCMV in vivo. However, these approaches have only a limited predictive 41 
ability. We measured the IFNγ T cell responses to an expanded panel of overlapping peptide pools 42 
specific for immunodominant HCMV proteins IE1/2, pp65, pp71, gB, UL144 and US3 in a cohort of 43 
D+R- kidney transplant recipients in a longitudinal analysis. Even with this increased antigen 44 
diversity, the results show that while all patients had detectable T cell responses, this did not correlate 45 
with control of HCMV replication in some. We wished to develop an assay that could directly 46 
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measure anti-HCMV cell-mediated immunity. We evaluated three approaches, stimulation of PBMC 47 
with (i) whole HCMV lysate or (ii) a defined panel of immunodominant HCMV peptides, or (iii) 48 
fully autologous infected cells co-cultured with PBMC or isolated CD8+ T cells or NK cells. 49 
Stimulation with HCMV lysate often generated non-specific antiviral responses while stimulation 50 
with immunodominant HCMV peptide pools produced responses which were not necessarily 51 
antiviral despite strong IFNγ production. We demonstrated that IFNγ was only a minor component of 52 
secreted antiviral activity. Finally, we used an antiviral assay system to measure the effect of whole 53 
PBMC, and isolated CD8+ T cells and NK cells to control HCMV in infected autologous dermal 54 
fibroblasts. The results show that both PBMC and especially CD8+ T cells from HCMV seropositive 55 
donors have highly specific antiviral activity against HCMV. In addition, we were able to show that 56 
NK cells were also antiviral, but the level of this control was highly variable between donors and not 57 
dependant on HCMV seropositivity. Using this approach, we show that non-viraemic D+R+ SOT 58 
recipients had significant & specific antiviral activity against HCMV.  59 
 60 
Words: 9312/12000 61 
1. Introduction 62 
Human cytomegalovirus remains a significant cause of mortality and morbidity in adult and 63 
paediatric solid organ (Razonable, 2005) and hematopoietic stem cell (Hiwarkar et al., 2013) 64 
transplant recipients. Viraemia in solid organ transplant (SOT) recipients can result from a primary 65 
infection, reinfection, superinfection with multiple strains (Cudini et al., 2019; Görzer et al., 2010), 66 
or from reactivation of the host’s own HCMV strain(s) (Atabani et al., 2012). HCMV viraemia and 67 
disease in SOT recipients is associated with a number of risk factors, including organ type (with 68 
larger transfers of lymphoid tissue conveying higher risk, due to the larger latent virus load present) 69 
(Razonable and Humar, 2013), the degree of immune suppression (required to prevent organ 70 
rejection) the SOT recipient is receiving, as well as other co-infections and co-morbidities and 71 
relative HCMV serostatus (Atabani et al., 2012; Razonable, 2005).  72 
Relative HCMV serostatus can be used to divide solid organ donors and recipients into four groups 73 
with distinct HCMV viraemia and disease risk profiles. Donor seronegative, recipient seronegative 74 
(D-R-) solid organ transplants have the lowest likelihood of HCMV infection or disease. Donor 75 
seronegative, recipient seropositive (D-R+) transplants have a low risk of viraemia, as the recipient 76 
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has pre-existing cellular immunity to HCMV and no exogenous HCMV strains are introduced by the 77 
donor organ; HCMV viraemia comes from reactivation of the recipient’s own virus(es). Donor 78 
seropositive, recipient seropositive transplants (D+R+) have an intermediate risk of viraemia, 79 
because while the recipient has pre-existing immunity, HCMV re-infection or superinfection by 80 
donor strains may occur, as well as reactivation of the recipient’s own HCMV. The highest risk of 81 
HCMV viraemia and disease is seen in donor seropositive, recipient seronegative (D+R-) transplants. 82 
In this situation, the donor organ can transmit HCMV to the immunologically HCMV-naïve 83 
recipient, causing primary infection with one or more HCMV strains (Atabani et al., 2012). 84 
Antiviral prophylaxis and pre-emptive treatment are important tools for the prevention and 85 
management of HCMV disease in immune suppressed populations (Lumley et al., 2019). Using a 86 
prophylactic treatment strategy, all patients considered at risk of HCMV viraemia and disease receive 87 
antiviral treatment for a defined period of time immediately post-transplant. In contrast, pre-emptive 88 
treatment monitors asymptomatic patients for evidence of HCMV replication (DNAemia measured 89 
by quantitative nucleic acid testing (QNAT)) and treats with antivirals once a threshold is reached 90 
(Razonable and Humar, 2019). In clinical practice, this means that pre-emptive treatment requires 91 
frequent (eg twice-weekly) monitoring of HCMV DNA in blood, and commencing antiviral 92 
treatment at a defined DNAemia threshold, for example 2520 IU/ml (Griffiths et al., 2016). Recent 93 
data suggest that the prophylactic strategy requires less intensive patient monitoring in SOT, and is 94 
associated with lower viraemia and a lower risk of HCMV reactivation/reinfection compared to pre-95 
emptive treatment (Griffiths, 2019). However prophylactic treatment also leads to an increased risk 96 
of late-onset disease due to poorer cell-mediated immunity in D+R- transplants (Limaye et al., 2019); 97 
and poorer patient outcomes, including reduced kidney function and increased risk of graft rejection 98 
(Blazquez-Navarro et al., 2019). There is conflicting evidence as to whether prophylaxis significantly 99 
increases the risk of drug resistance (Hakki and Chou, 2011; López-Aladid et al., 2017). However, it 100 
is notable that HCMV viraemia and disease only seems to occur in a subset of these ‘at-risk’ 101 
individuals.  102 
The occurrence of HCMV viraemia and disease in patient groups with T cell immune deficiencies 103 
(untreated HIV/AIDS, inborn errors of immunity) or suppression (SOT recipients) highlights the 104 
importance of cell-mediated immunity (CMI) in the control of HCMV (Bowen et al., 1997; Bunde et 105 
al., 2005; Fiala et al., 1986; Gerna et al., 2006; McLaughlin et al., 2017). The practice of clinical 106 
monitoring for development of HCMV-specific immunity using HCMV-specific interferon gamma 107 
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(IFNγ) production has been studied in both solid organ and haematopoietic stem cell transplant 108 
recipients and has gained traction in recent years. In solid organ transplant recipients, the utility of 109 
such an approach is in assessing the risk of late-onset HCMV disease after cessation of prophylaxis 110 
in high-risk (D+R-) transplant recipients, predicting seropositive (R+) patients who may 111 
spontaneously clear HCMV infection (Kumar et al., 2018), and predicting risk of relapse of HCMV 112 
viraemia or disease (Haidar et al., 2020). In contrast, the predictive power of CMI assays was much 113 
lower in high-risk seronegative (R-) SOT recipients (Haidar et al., 2020; Kumar et al., 2018), where 114 
an effective assay might yield the greatest benefit. In the haematopoietic stem cell transplant 115 
population, immune monitoring is used with pre-emptive treatment strategies and can be used to 116 
predict early or recurrent reactivation, to shorten duration of anti-HCMV therapy, and to predict 117 
individuals likely to clear HCMV infection spontaneously (Yong et al., 2018). The main advantage 118 
offered with immune monitoring is to allow clinicians to tailor the use of antiviral therapies, thereby 119 
reducing the attendant therapeutic complications, such as myelosuppression with 120 
ganciclovir/valganciclovir, and electrolyte imbalances with foscarnet. Better immune monitoring 121 
would also allow for the preparation of e.g. HCMV-specific therapeutic T cells in patients thought 122 
highly likely to fail antiviral therapy (Neuenhahn et al., 2017). This group would include patients 123 
with pre-existing antiviral resistance mutations or patients infected with more than one HCMV strain 124 
(Coaquette et al., 2004; Lisboa et al., 2011). These factors may overlap with and be exacerbated by 125 
poor cell-mediated antiviral immunity. However, the limitations of immune monitoring, such as high 126 
costs, slow turnaround times, and lack of standardisation remain to be addressed (Haidar et al., 2020). 127 
There are a number of assays currently used to provide an ex vivo measure of HCMV-specific 128 
cellular immunity. Immune monitoring assays can be broadly placed in to four groups. EliSpot-based 129 
assays, such as T-Spot (Kumar et al., 2018) and T-Track (Banas et al., 2017), use peptides from pp65 130 
and IE1/2 and enumerate CD4+ and CD8+ T cell responses. However, individuals responding to 131 
epitopes from other HCMV proteins would not be covered by these assays, although the assay is 132 
HLA-agnostic. While EliSpot-based assays can be adapted to analyse a wider range of antigens 133 
(whether with HCMV lysate or peptide pools), this approach is more often used for research than 134 
clinical assays (eg (Goodell et al., 2007; Jackson et al., 2017b; Mohty et al., 2004)). There are also 135 
ELISA-based assays, such as QuantiFERON-CMV (Qiagen) (Walker et al., 2007). QuantiFERON-136 
CMV measures CD8+ T cell responses to 22 defined epitopes from IE1 and 2, pp28, pp50, pp65 and 137 
gB with restricted HLA coverage, and may be confounded by lymphopenia (Giulieri and Manuel, 138 
2011). MHC class I HCMV tetramer/multimer peptide complex staining (Yong et al., 2018) allows 139 
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the detection and quantification of HCMV-specific cytotoxic CD8+ T cells, covering known epitopes 140 
in pp50, pp65 and IE1 (Borchers et al., 2011). These HCMV-specific CTLs are associated with 141 
protection from viraemia in some patient populations, although not currently considered predictive 142 
(Kotton et al., 2018). Flow cytometry-based intracellular cytokine staining is also used for research 143 
applications, but is not as widely used for diagnostic purposes (Fernández-Ruiz et al., 2018) because 144 
of the requirement for flow cytometry equipment and expertise (Rogers et al., 2020), despite its 145 
potential to predict both viraemia and disease (Kotton et al., 2018). Most non-flow cytometry-based 146 
approaches are restricted to peptides recognized specifically by HLA types more common in 147 
populations of European descent. More generally, these assays are measuring the ability of a T cell to 148 
respond to an antigen and using that as a correlate of inferred antiviral activity.  149 
The majority of these HCMV-immune monitoring assays, and particularly the EliSpot/FluoroSpot 150 
and ELISA-based assays, focus on production of a single cytokine in response to HCMV - IFNγ. 151 
There are problems with both the negative and positive predictive value of these assays (Chanouzas 152 
et al., 2018; Deborska-Materkowska et al., 2018; Fernández‐Ruiz et al., 2020; Jarque et al., 2018); 153 
while other prospective studies have found positive IFNγ ELIspot responses to be predictive of 154 
protection against HCMV viraemia or disease necessitating a change in treatment strategy (Kumar et 155 
al., 2019). IFNγ responses to HCMV as measured by ELISA and EliSpot are clearly measuring part – 156 
but not all – of HCMV CMI, because viraemia can occur in the presence of IFNγ responses to 157 
HCMV; and viraemia does not necessarily occur in the absence of IFNγ responses to HCMV. As 158 
such it is likely that other secreted and cell-mediated factors are involved, including CMI responses 159 
to epitopes not included in most commercial assays; other cytokines with antiviral activity; the 160 
responses of other arms of the immune system beyond CD8+ T cells (e.g. CD4+ T cells (Watkins et 161 
al., 2012); NK cells (Venema et al., 1994); monocyte-derived macrophages (Becker et al., 2018); γδ 162 
T cells (Kaminski et al., 2016; Knight et al., 2010); antibodies (Baraniak et al., 2018)); and host and 163 
viral genetic variation (Sezgin et al., 2019; Suárez et al., 2019).  164 
In this study we have examined by FluoroSpot the IFNγ response to overlapping peptides from a 165 
much broader range of immunodominant HCMV proteins in D+R- kidney transplant recipients 166 
experiencing primary HCMV infection, correlated with patient DNAemia over a time course post-167 
transplantation. These results show that detection of HCMV-specific T cells at frequencies similar to 168 
normal healthy controls was not predictive of the ability to control episodes of viraemia. We have 169 
also studied the antiviral activity of supernatants derived from PBMC stimulated with HCMV-170 
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infected cell lysate as well as immunodominant peptide pools in a virus dissemination assay system. 171 
Using this system, we demonstrated that lysate and peptide stimulation of PBMC are imperfect ways 172 
to measure HCMV secreted antiviral immunity, as many donors reacted non-specifically to lysate 173 
stimulation or did not produce antiviral responses to peptide stimulation. Finally, we utilised a fully 174 
autologous virus dissemination assay cocultured with whole PBMC, CD8+ T cells or NK cells to 175 
determine the antiviral capacity of these immune effectors against HCMV-infected fibroblasts. In 176 
healthy donors both whole PBMC and isolated CD8+ T cells were highly effective in the control of 177 
HCMV replication. The results of the NK cell cocultures show that while some donors were able to 178 
control HCMV replication, other donors had much poorer antiviral activity. We then demonstrate 179 
that PBMC and CD8+ T cells derived from D+R+ kidney transplant recipients who control their 180 
viraemia post-transplant, could control HCMV dissemination similarly to an immunocompetent, 181 
healthy HCMV seropositive individual. Our data lead us to conclude that autologous cell-mediated 182 
assays are the most powerful way to characterise the functionality of the antiviral immune response 183 
to HCMV. Importantly, this approach will allow us to stratify patients based on the ability of their 184 
CMI to control HCMV ex vivo and, furthermore, could have important implications for our 185 
understanding of the key elements of the immune response which are important for the control of 186 
HCMV.  187 
2. Materials and methods 188 
Recruitment: kidney transplant recipients 189 
Seven seropositive donor to seronegative recipient (D+R-) kidney transplant patients were recruited 190 
by Academisch Medisch Centrum, (AMC) Amsterdam, who experienced primary HCMV infection 191 
post-transplantation. Transplants took place between 2003-2009. Ethical permission was granted by 192 
the Medical Ethics Committee of the AMC, Amsterdam and all patients gave informed written 193 
consent in accordance with the Declaration of Helsinki. Donor and recipient serostatus were defined 194 
using a microparticle enzyme immunoassay as previously described (Remmerswaal et al., 2012). 195 
PBMC were collected at multiple time points after transplantation, with subsequent samples collected 196 
at varying time points up to a maximum of 158 weeks post-transplantation, isolated by density 197 
centrifugation and cryopreserved (Remmerswaal et al., 2012). Virus load monitoring was performed 198 
by quantitative PCR (qPCR) as previously described (Boom et al., 1999). PBMC were a kind gift 199 
from Professors I.J.M. ten Berge and R.A.W. van Lier (Amsterdam Renal Transplant Unit). 200 
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Four seropositive donor to seropositive recipient (D+R+) kidney transplant patients were recruited by 201 
the Royal Free Hospital, London. Ethical permission for “UCL17-0008 Analysis Of 202 
Cytomegalovirus Pathogenesis In Solid Organ Transplant Patients Study” was granted by the London 203 
- Queen Square Research Ethics Committee (REC reference 17/LO/0916). Informed written consent 204 
was obtained from all patients included in this study prior to providing pseudo-anonymised research 205 
samples (blood, urine, saliva, skin and bile). No patients in the UCL cohort received antiviral therapy 206 
as they did not develop detectable DNAemia, following previously published treatment guidelines 207 
(Griffiths et al., 2016). Virus load (DNAemia) monitoring was performed by qPCR as previously 208 
described (Atabani et al., 2012; Mattes et al., 2005).  209 
For all donors used in this study, PBMC derived from blood samples were collected and stored in a 210 
cell bank for subsequent analysis. The study was designed in this way for two reasons, firstly because 211 
of the time required to grow out a human dermal fibroblast line (weeks) which are required for the 212 
autologous viral dissemination assays. Secondly, the assays developed in these studies are to be used 213 
in a longitudinal analysis of D+R- patients post-transplantation to understand which immune 214 
responses confer protection from viraemia. Blood samples collected for PBMC isolation and 215 
determination of viraemia will be taken at regular time points post-transplantation so that PBMC 216 
from time points with and without viraemia could be assayed at multiple time points in parallel. T 217 
cell responses from normal healthy volunteers were thus treated in same way. Our freezing and 218 
thawing protocols are defined and consistent, and where appropriate an anti CD3/CD28 positive 219 
control is included, such that donors that failure to respond to polyclonal stimulation are excluded 220 
from analysis. 221 
Patients are summarised in Table 1 and supplementary tables 1 (D+R-) and 2 (D+R+) 222 
Recruitment: healthy volunteers 223 
HCMV seronegative and seropositive individuals were recruited in younger (<40 years of age) and 224 
older (65> years of age) groups, donating either PBMC (ARIA study (Jackson et al., 2017b)) or 225 
PBMC and autologous primary dermal fibroblasts (AQUARIA study).  226 
HCMV seropositive and seronegative donors were recruited in three stages. Ten donors were 227 
recruited locally with ethical approval from the Cambridge Central Research Ethics Committee 228 
(97/092). Eleven donors were previously recruited by the NIHR BioResource Centre Cambridge 229 
through the ARIA study (Jackson et al., 2017b), with ethical approval from the Cambridge Human 230 
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Biology Research Ethics Committee (HBREC.2014.07). Sixteen donors were recruited by the NIHR 231 
BioResource Centre Cambridge through the AQUARIA study, with ethical approval from the North 232 
of Scotland Research Ethics Committee 1 (NS/17/0110). Donors were excluded if they were 233 
receiving immunosuppressive therapy, eg cyclosporins or methotrexate.  234 
 In each case, informed written consent was obtained from all volunteers in accordance with the 235 
Declaration of Helsinki.  236 
Healthy volunteers are summarised in Table 1 237 
Isolation of human dermal fibroblasts 238 
Primary human dermal fibroblasts (HDFs) were obtained from individual donors in the AQUARIA 239 
study and the D+R+ kidney transplant cohort. A 2-mm punch biopsy was obtained from each donor. 240 
HDFs were grown out from this biopsy following a previously published protocol (Poole et al., 241 
2014), modified to use DMEM (Poole et al., 2020). 242 
Peripheral Blood Mononuclear Cell (PBMC) Isolation 243 
Peripheral blood mononuclear cells were isolated from heparinised blood samples using 244 
Histopaque®-1077 (Sigma-Aldrich, Poole, UK) or Lymphoprep (Axis-shield, Oslo, Norway) density 245 
gradient centrifugation. HCMV serostatus was assessed using an IgG enzyme-linked immunosorbent 246 
assay (Trinity Biotech Plc, Co. Wicklow, Ireland). Patient, ARIA and local donor PBMC were frozen 247 
in liquid nitrogen in a 10% dimethyl sulfoxide (DMSO) (Sigma-Aldrich) and 90% SeraPlus fetal 248 
bovine serum (PAN Biotech, Wimborne, UK) solution; AQUARIA PBMC were frozen in a serum-249 
free freezing media composed of 60% IMDM (Iscove's Modified Dulbecco's Medium, Sigma), 10% 250 
DMSO and 30% Panexin serum replacement (PAN Biotech). Frozen PBMC were rapidly thawed, 251 
and the freezing medium was diluted into 10ml of fresh X-Vivo 15 (Lonza, Slough, UK). PBMC 252 
were incubated at 37°C with 10U/ml DNase (Benzonase, Merck-Millipore via Sigma-Aldrich) for 1h, 253 
followed by resuspension in fresh media and an overnight incubation at 37°C. 254 
Specific cell subtype isolation 255 
PBMC were enriched for CD8+ T cells or NK cells by magnetically activated cell sorting (MACS) 256 
using CD8+ T cell (130-096-495) or NK cell (130-092-657) isolation kits (Miltenyi Biotech, Woking, 257 
UK), according to the manufacturer’s instructions. Cells were separated by use of an autoMACS Pro 258 
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separator (Miltenyi Biotech). The efficiency of depletion was determined by staining cells as 259 
described in the phenotyping method below. Depletions performed in this manner resulted in 0-0.3% 260 
residual CD4+ T cell content of CD8+ cell fractions, and 0.4-3.7% CD3+ T cell contamination of NK 261 
cell fractions. 262 
Fluorescently labelled Merlin (mCherry-P2A-UL36 [vICA], GFP-UL32 [pp150]) 263 
The virus used in this study was based on a BAC cloned version of HCMV strain Merlin (Wilkinson 264 
et al., 2015). This contains the complete wildtype HCMV genome, with the exception of point 265 
mutations in RL13 and UL128, which enhance growth in fibroblasts (Stanton et al., 2010). Two 266 
genes were tagged with fluorescent markers. UL36 was linked to mCherry via a P2A linker. This 267 
arrangement results in expression of mCherry at immediate early times (Nightingale et al., 2018). 268 
UL32 was linked directly to GFP via a six amino-acid linker, and results in GFP expression at late 269 
times (Weekes et al., 2014). Both constructs were generated by recombineering as previously 270 
described (Stanton et al., 2008). In both cases, a recombineering cassette expressing kanR, lacZa and 271 
rpsL was first inserted at the site of modification, following PCR amplification using primers in 272 
Supplementary Table 3. For GFP fusions to UL32, the primers listed in Supplementary Table 3 were 273 
used to amplify GFP and switch the recombineering cassette for the linker-GFP sequence. For 274 
insertion of P2A-mCherry after UL36, the insertion was gene synthesized by Geneart, digested to 275 
release it from its original vector, gel purified, and used to replace the recombineering cassette. All 276 
constructs were sequenced by Sanger sequencing across the site of modification, including any 277 
inserted sequence. 278 
Virus propagation 279 
HCMV strain Merlin mCherry-P2A-UL36 GFP-UL32 was grown in human foreskin fibroblasts 280 
(HFF), following the protocol in (Wills et al., 2005). The infectious titre and PFU were calculated 281 
using the method in (Jackson et al., 2017a). 282 
HCMV-infected cell lysate and control fibroblast lysate 283 
One T175 flask of MRC-5 fibroblasts was maintained in DMEM [Sigma, Poole, UK] with 10% FCS 284 
[PAA, Linz, Austria] and pen-strep [10^5 IU penicillin/L, and 100 mg streptomycin/L (Invitrogen 285 
Life Technologies)]. When cells were 80% confluent, they were infected with dual-colour Merlin and 286 
the virus was propagated for 14 days at 37°C in a 5% CO2 humified atmosphere. When 80% of cells 287 
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were mCherry+ or mCherry+GFP+ by fluorescent microscopy, the infected cells were harvested 288 
using trypsin. A second T175 flask of MRC-5 fibroblasts was used as control fibroblast lysate and 289 
was harvested when cells were 95% confluent. Cells were resuspended in 10ml DMEM with 10% 290 
FBS and placed in a 50ml Falcon. Cells were subjected to three freeze-thaw cycles to lyse the cells, 291 
alternating between a dry-ice/ethanol bath and 37°C water bath. The lysed cell suspension was then 292 
centrifuged for seven minutes at 700RPM and the supernatant (the lysate) drawn off and frozen in 293 
1ml aliquots were stored at -80°C until further use. Lysates were heat-treated at 56°C for 30 minutes 294 
before subsequent application (Hodinka, 2007; Nokta et al., 1996). 295 
HCMV ORF peptide pools 296 
Seven HCMV proteins were selected based on previously demonstrated immunogenicity (Jackson et 297 
al., 2014, 2017a) and peptide libraries comprising consecutive 15mer peptides overlapping by 10 298 
amino acid were synthesized by ProImmune PEPScreen (Oxford, UK) and JPT Peptide Technologies 299 
GmbH (Berlin, Germany). Individual lyophilised peptides were reconstituted and used as previously 300 
described (Jackson et al., 2014) in peptide pools at a concentration of 5µg/ml/peptide. The peptide 301 
pools covered the following ORFs: gB (UL55); pp65 (UL83) and UL144; IE1 (UL123) and IE2 302 
(UL122); pp71 (UL82) and US3.  303 
Cytokine quantification by Enzyme-Linked Immunosorbent Assay (ELISA) 304 
The Human IFNγ ELISA MAX Standard Set (Biolegend, London, UK) was used to quantify IFNγ 305 
concentrations in supernatants. ELISAs were performed according to the manufacturer’s 306 
recommended protocol. 307 
Detection of cytokine production by FluoroSpot 308 
To maximise available cell numbers, 1 x 10^5 total PBMC were suspended in X-VIVO 15 (Lonza, 309 
Slough, UK) supplemented with 5% Human AB serum (Sigma Aldrich). PBMC were incubated in 310 
pre-coated human IFNγ and IL-10, or IFNγ, IL-10, and TNFα FluoroSpot plates (Mabtech AB, 311 
Nacka Strand, Sweden) in triplicate with ORF peptide pools (final peptide concentration 2µg/ml 312 
following dilution with X-Vivo-15) and an unstimulated and positive control mix [containing anti-313 
CD3 and anti-CD28 (Mabtech AB) or colloidal anti-CD3 and anti-CD28 (Human T cell TransAct, 314 
Miltenyi Biotech), at 37°C for 48 h. Cells and media were decanted from the plate and the assay 315 
developed following the manufacturer’s protocol. Developed plates were read using an AID iSpot 316 
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reader (Oxford Biosystems, Oxford, UK) and counted using AID EliSpot v7 software (Autoimmun 317 
Diagnostika GmbH, Strasberg, Germany).  318 
Donor results were discounted from further analysis if there was greater than 1000 spot forming units 319 
(sfu) per well. The sfu response in the positive control (mitogen stimulation) wells had to be at least 320 
100 sfu/well greater than the background sfu/well, otherwise the sample failed quality control and 321 
was excluded. The mean sfu of triplicate wells were converted to sfu per 10^6 cells, the mean 322 
background response (sfu/10^6 cells) was deducted from the mean responding wells. The cut off to 323 
define a positive IFNγ response was responses greater than 100 sfu/10^6 cells, negative responses 324 
were below this. The cut off was determined by comparing the distribution of the responses from 325 
HCMV seropositive and seronegative donors to HCMV protein stimulation and the positive control 326 
in our previous ARIA study results (Jackson et al., 2017b). 327 
Generation of supernatants following lysate stimulation 328 
3 x 10^5 total PBMC were suspended in X-VIVO 15 (Lonza, Slough, UK) in a 5ml polypropylene 329 
tube and stimulated with heat inactivated HCMV [Merlin]-infected fibroblast lysate or uninfected 330 
fibroblast lysate, and positive control mixes (anti-CD3 and anti-CD28, as above). They were 331 
incubated at 37°C, in a 5% CO2 atmosphere for 48h. Tubes were spun for 10mins at 2000RPM to 332 
pellet the PBMC. 2ml media (the supernatant) was then removed from each tube without dislodging 333 
the cell pellet and frozen at -80°C. 334 
Generation of supernatants following peptide stimulation 335 
3 x 10^5 total PBMC were suspended in X-VIVO 15 (Lonza, Slough, UK) in a 5ml polypropylene 336 
tube and stimulated with ORF peptide pools and unstimulated (X-VIVO 15) and positive control 337 
mixes. They were incubated at 37°C in a 5% CO2 atmosphere for 48h and supernatants harvested as 338 
above. 339 
Virus dissemination assay: non-autologous  340 
Human fetal foreskin fibroblasts (HFFFs) were maintained in DMEM [Sigma, Poole, UK] with 10% 341 
FCS [PAA, Linz, Austria] and pen-strep [10^5 IU penicillin/L, and 100 mg streptomycin/L 342 
(Invitrogen Life Technologies)]. HFFFs were seeded at 2.5x10^4 cells/well in a 96 well plate. After 343 
48 hours, cells were confluent and were infected at a low MOI (0.01) with mCherry-GFP-Merlin. 344 
After a further 24 hours, 75ul of lysate or peptide-stimulated supernatant was added to each well. 345 
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After 9-11 days, cells were harvested with trypsin and fixed in a 2% PFA solution for flow cytometry 346 
analysis of viral dissemination. 347 
Viral spread in each well was determined as a percentage of control wells lacking supernatants using 348 
the following equation ([Experimental % of infected cells - background % of HFFF-only control] / 349 
[% of infected HFFF control without effector cells/supernatants - background % of HFFF-only 350 
control]) x 100.  351 
Virus dissemination assay: autologous 352 
Human primary dermal fibroblasts (HDFs) were maintained in DMEM [Sigma, Poole, UK] with 353 
20% FCS [PAA, Linz, Austria] and pen-strep [10^5 IU penicillin/L, and 100 mg streptomycin/L 354 
(Invitrogen Life Technologies)]. Where paired HDFs and effector cells (PBMC; CD8+; NK) were 355 
available from healthy volunteers, 1x10^4 HDFs were seeded in each well of a half-area 96 well 356 
plate (Greiner Bio-One, Stroudwater, UK). After 48 hours, cells were confluent and were infected at 357 
a low MOI (0.01) with mCherry-GFP-Merlin HCMV. After a further 24 hours, cells were seeded at a 358 
range of effector to target ratios in X-Vivo 15 (Lonza, Slough, UK). After 10-14 days, PBMC or 359 
effector cells were washed off and HDFs were harvested with trypsin and fixed in a 2% PFA solution 360 
for flow cytometry analysis of viral spread. 361 
Viral spread in each well was determined as described previously. 362 
Phenotyping 363 
10^5 total PBMC was stained in separate tubes with two phenotyping cocktails containing 2ul of 364 
each antibody: 365 
T cell antibody mix: anti-CD3- fluorescein isothiocyanate (FITC), clone UCHT1; anti-CD4- 366 
phycoerythrin (PE), clone RPA-T4; anti-CD8a-peridinin-chlorophyll protein - cyanine 5.5 (PerCP 367 
Cy5.5), clone RPA-8a (all BioLegend, London, UK), LIVE/DEAD Fixable Far Red Dead Cell Stain 368 
Kit (Thermo Fisher Scientific) 369 
NK cell antibody mix: anti-CD3-FITC; anti-CD8-PerCP Cy5.5 (both as before); anti-CD56-PE, 370 
clone B159 (BD Pharmingen); LIVE/DEAD Fixable Far Red Dead Cell Stain Kit. 371 
Flow cytometry 372 
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Flow cytometry analysis of dual-colour virus dissemination was performed on the BD Fortessa2 or 373 
Thermo Fisher Attune NxT flow cytometers. PBMC phenotyping was performed on the BD Accuri 374 
C6 flow cytometer. Data were analysed with FlowJo v10 (Becton Dickinson, Wokingham, UK). 375 
Statistical and graphical analysis 376 
Data presentation and statistical analyses was performed using GraphPad Prism v8. Statistical 377 
significance for one-tailed T tests was determined with an alpha = 0.05, without assuming a 378 
consistent standard deviation between populations. 379 
3. Results 380 
Longitudinal detection of HCMV-specific IFNγ CD3+ T cell responses in D+R- kidney 381 
transplant recipients did not predict resolution of viraemia  382 
IFNγ T cell responses to HCMV in vitro have previously been used as a surrogate measure of the 383 
level of cell-mediated immunity to HCMV in vivo. To begin testing this assumption, we 384 
characterised the development of IFNγ T cell responses following primary HCMV infection. To do 385 
this, CD3+ T cell IFNγ responses to HCMV peptide pools were measured by Fluorospot on a cohort 386 
of D+R- kidney transplant patients, all of whom experienced primary HCMV infection following 387 
transplantation. In the seven patients studied, all developed robust IFNγ responses to a range of 388 
HCMV peptide pools, covering lytic proteins gB, IE1, IE2, US3, pp65, UL144 and pp71, responses 389 
enumerated by FluoroSpot [Figure 1] and [Supplementary figure 1].  390 
However, these longitudinal analyses revealed examples of two broadly distinct patterns of response 391 
in this cohort [Figure 1]. In some patients (3/7 e.g. Pt365), we observed the generation of a HCMV-392 
specific IFNy CD3+ T cell response which was sustained over time and correlated with the resolution 393 
of initial viraemia. Subsequent episodes of viraemia where not observed after this response became 394 
detectable. In other patients, viraemia recurred once (3/7 e.g. Pt574 [Supplementary figure 1]) or 395 
several times (1/7 eg Pt352 – [Figure 1]), despite detectable HCMV-specific IFNy CD3+ T cell 396 
responses of similar magnitude being present at the times of recrudescence. As such, the results show 397 
that in this group of patients, CD3+ T cell IFNγ responses as measured by FluoroSpot were not 398 
necessarily predictive of the resolution of CMV viraemia, even when a broad selection of highly 399 
immunogenic HCMV peptide pools was used. Importantly, a comparison of the magnitude of these 400 
responses with a previously studied cohort of healthy seropositive donors in the same age range as 401 
  HCMV immune monitoring 
 
15 
each transplant recipient (Jackson et al., 2017b) revealed the CD3+ T cell IFNγ FluoroSpot responses 402 
of these seven D+R- patients were of a similar magnitude and breadth arguing that these patients can 403 
generate substantial T cell responses when measured by IFNy Fluorospot. 404 
Determination of antiviral efficacy of HCMV antigen stimulated PBMC and its correlation to 405 
IFNγ detection-based assays 406 
We speculated that one explanation for the inconsistent predictive power of simply measuring CD3+ 407 
HCMV-specific T cell IFNγ responses as a correlate with in vivo HCMV control could be that other 408 
cytokines and secreted factors may also play an important role in antiviral T cell immunity to HCMV 409 
(Mason et al., 2013; Nachtwey and Spencer, 2008; Siewiera et al., 2013).  410 
In order to address this the capacity of the CD3+ T cells to control viral replication we adapted a viral 411 
dissemination assay (VDA) previously used by our group to quantify the spread of virus through 412 
indicator fibroblasts co-cultured with NK cells or CD8+ T cells (Chen et al., 2016; Jackson et al., 413 
2014). Using a dual mCherry-GFP expressing strain of HCMV (Merlin), the progression of infection 414 
can be assayed. Infected cells express mCherry from immediate-early times post infection (linked to 415 
UL36-P2A-mCherry) and are both mCherry and GFP+ (fused to UL32 [pp150 - tegument protein]) at 416 
late times post infection. Following a low MOI infection, the virus spreads through fibroblasts over 417 
time. The infected mCherry+ and mCherry+ GFP+ cells can be visualised using fluorescent 418 
microscopy and enumerated by two colour flow cytometry [Figure 2A], quantifying viral 419 
dissemination kinetics over a series of time points [Figure 2B]. 420 
Prior to the specific analysis of the supernatants derived from T cells stimulated by HCMV antigens, 421 
we first determined whether supernatant from PBMC incubated with anti-CD3 and anti-CD28 422 
antibodies to polyclonally activate the T cells (Trickett and Kwan, 2003) was antiviral compared to 423 
unstimulated PBMC control from the same donor. To test for any antiviral activity, supernatants were 424 
added to cultures of HFF fibroblasts that had been previously infected with HCMV overnight at low 425 
MOI (0.01). The data show that supernatants taken from antibody-stimulated T cells reduced the 426 
percentage of both mCherry+ fibroblasts and mCherry+ GFP+ fibroblasts in a titratable manner 427 
[Figure 2C]. Although some antiviral activity was evident using supernatants from unstimulated 428 
PBMC (particularly when fibroblasts were analysed for GFP expression), this activity was 429 
considerably lower than following polyclonal T cell activation. An analysis of supernatants from 430 
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activated T cells from multiple donors (n = 10) revealed that the level of antiviral activity induced 431 
varied considerably between donors [Figure 2D].  432 
It was noted that following overnight infection, and addition of PBMC derived supernatants, that the 433 
initial infected cells (identified as mCherry+) proceeded to late gene expression (ie became GFP+) 434 
after a further 48hours incubation, even in the presence of a supernatant identified as antiviral. We 435 
hypothesised, therefore, that the antiviral effects observed were due to inhibition of the secondary 436 
infections that occur in our VDA rather than an inhibition of the first round of infected cells. These 437 
subsequent rounds of infection (spread) can be measured if immediate early gene expression occurs 438 
(mCherry+ cells) and/or subsequent progression to late viral gene expression by GFP expression is 439 
impacted. As such, two scenarios are possible: uninfected cells incubated with these supernatants 440 
might become refractory to HCMV infection or induced into an antiviral state which disrupts normal 441 
temporal viral gene expression between immediate early and late viral gene expression. We therefore 442 
subsequently define a reduction in the relative percentage of cells which are mCherry+GFP- as a 443 
reduction in virus spread in the culture. If a reduction in the relative percentage of cells which are 444 
mCherry+ and GFP+ is observed (and thus a reduction in progression to late gene expression), we 445 
can use this as a proxy for a reduction in the number of new infections in the VDA capable of 446 
producing new infectious virus particles. 447 
Having established that we could generate and define antiviral supernatants by polyclonal T cell 448 
stimulation of PBMC, we then wished to study the HCMV-specific secreted antiviral immune 449 
response of PBMC from healthy seropositive volunteers. Healthy donor PBMC was stimulated with 450 
heat-treated HCMV-infected fibroblast lysate (‘lysate’), and harvested supernatants tested for 451 
antiviral activity in our VDA. The results show that the outcome of PBMC stimulation is variable. 452 
Some seropositive donors (e.g. ARIA219) generated HCMV-specific antiviral supernatants, as they 453 
reduced the number of mCherry+GFP+ fibroblasts. In contrast, supernatants from PBMC taken from 454 
donor ARIA177 show comparable inhibition of virus by both the uninfected control fibroblast lysate 455 
and the HCMV-infected lysate stimulation. Other donors had a weak antiviral response to HCMV, 456 
such as ARIA211 [Figure 3A]. ARIA177 supported the hypothesis that non-self antigens from the 457 
fibroblasts used to produce the lysate may have stimulated a non-specific antiviral response from 458 
some donors – which would be consistent with  our observations with supernatants from polyclonally 459 
stimulated T cells. We therefore adapted this assay to use the gB, IE1, IE2, US3, pp65, UL144 and 460 
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pp71 pools of immunodominant HCMV peptides, recognised by both CD8+ and CD4+ T cells for 461 
PBMC stimulation (Jackson et al., 2017b; Sylwester et al., 2005). 462 
Healthy seropositive donor PBMC was thus stimulated with these HCMV peptide pools for 48h and 463 
the supernatant harvested and added to the VDA at 24hpi. Here supernatants from unstimulated 464 
PBMC were used as a negative control and polyclonal stimulation was used as a positive control for 465 
antiviral activity. The results show that two of the four donors tested produced HCMV-specific 466 
antiviral supernatants in response to stimulation with one or more of the peptide pools, while two 467 
other donors (CMV319 and CMV332) did not produce an antiviral response following peptide 468 
stimulation of PBMC [Figure 3B].  Hypothetically, the supernatants harvested from donors CMV319 469 
and CMV332 may not have been antiviral in a VDA because these donors did not have memory T 470 
cells to any of the HCMV peptides used to stimulate the T cells. To investigate this, we quantified the 471 
HCMV peptide specific IFNγ CD3+ T cell responses FluoroSpot of PBMC from CMV319 and 472 
CMV332, alongside CMV1801. The results show that CMV1801 had positive FluoroSpot responses 473 
to pools containing peptides covering pp71/US3 [Figure 4A], CMV332 had positive FluoroSpot 474 
responses to pools containing peptides covering pp65/UL144 and IE1&2 [Figure 4B)] and CMV319 475 
had positive IFNγ FluoroSpot responses to peptides from IE2 and pp65 (data not shown).  476 
This approach revealed a disconnect between the detection of HCMV specific IFNγ responses (by 477 
FluoroSpot) and the ability of these supernatants to exert antiviral activity. Both CMV1801 and 478 
CMV332 had positive IFNγ CD3+ T cell responses to multiple HCMV peptide pools and in some 479 
cases at higher frequency (e.g. pp65/UL144 and IE1/2), yet the supernatant from CMV332 was not 480 
antiviral in the VDA [Figure 3B, 4A, 4B]. We therefore speculated that IFNγ was not the key 481 
cytokine that determines antiviral activity in the supernatants. To address this, HCMV peptide pools 482 
were used to stimulate PBMC from donor CMV1801 for analysis in parallel. Specifically, one in an 483 
IFNγ FluoroSpot plate (this would enumerate the T cell response and deplete free IFNγ) and one in a 484 
non-antibody coated microtitre plate so that IFNγ was present in the supernatant. Depletion of IFNγ 485 
was verified by ELISA [Figure 4C] and also analysed for antiviral activity by VDA [Figure 4D]. 486 
The results show that despite CMV1801 having IFNγ-producing T cells specific for pp65/UL144 and 487 
IE1&2 as well as pp71/US3, only supernatants from pp71/US3-stimulated T cells exhibited antiviral 488 
activity. Furthermore, this activity remained following depletion of IFNγ from those supernatants. 489 
Taken together, these data support our hypothesis that other factors, beyond IFNγ, are important to 490 
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the secreted antiviral immune response to HCMV. Additionally, their identification may reveal 491 
biomarkers of HCMV immunity.  492 
 493 
PBMC and CD8+ T cells control HCMV in an autologous in vitro co-culture viral dissemination 494 
assay 495 
Thus far our studies have focused on the anti-viral activity of cytokines produced by stimulated T 496 
cells. However, direct T cell-mediated cytotoxicity is an important mechanism of control of viral 497 
infection. We previously developed an assay to quantify CD8+ T cell and NK cell-mediated antiviral 498 
immunity, measuring the lymphocyte-mediated inhibition of dissemination of HCMV through a 499 
permissive autologous primary human fibroblast monolayer (Chen et al., 2016; Jackson et al., 2014, 500 
2019). Similar assays used in other laboratories have utilised partially HLA-matched fibroblasts and 501 
cytotoxic T lymphocytes (Sinzger et al., 2007) or measured lysis of HCMV-infected autologous 502 
fibroblasts with various NK cell clones derived from independent donors (Carr et al., 2002). We 503 
therefore wanted to assess the ability of whole PBMC, CD8+ T cells and NK cells from a cohort of 504 
seropositive and seronegative donors to control HCMV in a fully autologous experimental system, 505 
and to assess the relative contributions of these cell subsets (and their secreted antiviral factors) to 506 
that control. This approach also allows us to directly compare the antiviral efficacy of different cell 507 
subsets from the same donor in the same experiment.  508 
Primary autologous dermal fibroblasts were infected at a low MOI (0.01), 24h later these were co-509 
cultured with either total PBMC or purified CD8+ T cells or NK cells, across a range of effector to 510 
target (E:T) cell ratios. After incubation for 10-14 days, fibroblasts were analysed by flow cytometry 511 
for mCherry and GFP expression. This comparison enabled us to determine the HCMV specificity of 512 
this approach when purified CD8+ T cells were used from both HCMV seropositive and seronegative 513 
donors. The use of whole PBMC enables an assessment of the antiviral capacity of innate immune 514 
cells (NK cells and monocytes) as well as adaptive immune cells (CD8+ T cells and gamma-delta (γδ) 515 
T cells). 516 
The results are depicted using violin plots which show both the frequency distribution of the VDA by 517 
population (eg seropositive donor PBMC control of virus spread), and the individual data points for 518 
each donor. All data are normalised such that the infected controls for each donor were set as 100% 519 
infection, and the uninfected controls were set at 0% infection. At an E:T ratio of 2.5:1, HDFs 520 
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cocultured with PBMC from seropositive donors inhibited virus infected cells to between 0.6-15.4% 521 
of the normalised viral spread (as evidenced by mCherry+ cells) of the infection control. At the same 522 
E:T ratio, HDFs cocultured with PBMC from seronegative donors inhibited virus infected cells to 523 
between 34.9-100% of the normalised viral spread (mCherry+ cells) of the infection control. The data 524 
show PBMC from HCMV seropositive donors (n=8) were significantly better at controlling viral 525 
spread (mCherry+ cells) than PBMC from the HCMV seronegative cohort (n = 8) at E:T ratios of 5-526 
0.63:1. Similarly, the number of cells that progressed to late stage infection (GFP+) was significantly 527 
decreased in the HCMV seropositives versus the HCMV seronegative cohort at E:T ratios of 2.5-528 
0.63:1 [Figure 5].  529 
We next analysed the antiviral capacity and specificity of purified CD8+ T cells from both HCMV 530 
seropositive and seronegative individuals [Figure 6]. The data show that CD8+ T cells from HCMV 531 
seropositive donors were significantly more effective over a range of E:T ratios at inhibiting viral 532 
spread (mCherry+) and infectious virus production (GFP+) compared to CD8+ T cells from HCMV 533 
seronegative donors. We also noted that at the higher E:T ratios CD8+ T cells from HCMV 534 
seronegative donors were capable of exerting a level of control, but this was lost rapidly, with only 535 
HCMV-specific responses observed at E:T ratios of 2.5:1 and lower. At an E:T ratio of 2.5:1, HDFs 536 
cocultured with CD8+ T cells from seropositive donors inhibited virus infected cells to between 0.5-537 
54.1% of the normalised viral spread (mCherry+ cells) of the infection control. At the same E:T ratio, 538 
HDFs cocultured with CD8+ T cells from seronegative donors inhibited virus infected cells to 539 
between 70-125% of the viral spread (mCherry+ cells) of the infection control. 540 
Finally, we analysed NK cells purified from PBMC. In contrast to the results observed with PBMC 541 
and CD8+ T cells, the ability of NK cells to control HCMV did not vary significantly by donor 542 
serostatus (seropositive n = 8, seronegative n = 5) [Figure 7]. It was also notable that NK cell control 543 
of virus spread (mCherry+ only cells) was poor compared to the control exerted by CD8+ T cells 544 
from HCMV seropositive donors over the same range of E:T ratios. At an E:T ratio of 2.5:1, 545 
seropositive donors reduced the normalised viral spread (mCherry+ cells) to 24.8-114.8% compared 546 
to the infection control, while seronegative donors reduced the normalised viral spread to 40.9-79.2% 547 
compared to the infection control. It could also be seen from the violin plots that some donors’ NK 548 
cells exerted better viral control than others. In order to further illustrate this, we directly compared 549 
the data from two HCMV seropositive donors in more detail [Supplementary figure 2]. NK cells 550 
from donor AQU002 had high level virus control (controlling virus spread and late gene expression), 551 
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while NK cells from AQU003 were unable to control virus spread and had significantly less ability to 552 
control late virus gene expression. 553 
 554 
HCMV-seropositive solid organ transplant recipients (D+R+) showed comparable in vitro 555 
control of viral dissemination to healthy controls 556 
In our original analysis of HCMV-specific CD3+ T cell IFNγ responses to HCMV lytic peptides, we 557 
show that the development of these T cells was not predictive of resolution/recrudescence of 558 
viraemia in a number (n=7) of individuals in the D+R- kidney transplant cohort [Figure 1]. 559 
Approximately half of D+R+ transplant recipients develop viraemia post kidney or liver transplant, 560 
but have shorter duration of viraemia than D+R- patients suggesting pre-existing mature HCMV 561 
immune responses are better able to control viraemia (Atabani et al., 2012). In light of our analysis of 562 
cell-mediated immunity by IFNγ Fluorospot and VDA in both HCMV seropositive and seronegative 563 
healthy individuals, we tested the hypothesis that seropositive transplant recipients who do not 564 
develop viraemia have in vitro CMI more similar to healthy seropositives than healthy seronegatives 565 
in our assays.  566 
To investigate this, we identified four R+ patients who received a D+ organ who were not on 567 
antiviral prophylaxis and did not experience detectable viraemia post-transplantation. In this R+ 568 
cohort, the HCMV-specific CD3+ T cell IFNγ responses as well as total PBMC, CD8+ T cells and NK 569 
cells by autologous VDA were analysed. Total PBMC from each R+ individual, collected 570 
approximately three months (72-110 days) post kidney transplant, were stimulated with a panel of 571 
HCMV peptide pools as before, and the responses enumerated by IFNγ FluoroSpot [Supplementary 572 
figure 3]. The results show all the recipients had a detectable T cell response to at least one of the 573 
peptide pools. Recipient R02-00079 made IFNγ T cell responses to all the pools tested, R02-00005 to 574 
all but one pool, and R02-00058 and R02-00109 to a single pool each. 575 
We next determined the anti-HCMV activity of the PBMC, CD8+ and NK cells derived from the 576 
same R+ kidney transplant recipients. The results demonstrate that PBMC derived from the 577 
seropositive kidney transplant recipients three months post-transplant were just as effective at 578 
controlling HCMV as healthy seropositive PBMC and clearly different from the response in 579 
seronegatives [Figure 8A]. At an E:T ratio of 1.25, D+R+ PBMC from time point T3 (approximately 580 
three months post-transplant) controlled the spread of HCMV with a range 0.7-24.5% of the infected 581 
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control (mCherry+ cells), compared to a range of 1.3-55.6% in healthy seropositives and 33-92.7% in 582 
healthy seronegatives. This was also recapitulated in CD8+ T cells analyses where again R+ patient 583 
cells had a similar pattern of control to CD8+ T cells derived from healthy seropositives [Figure 8B]. 584 
Correspondingly, NK cells from the R+ kidney transplant recipients had a similar range of virus 585 
control to both HCMV seropositive and seronegative healthy donors [Figure 8C]. 586 
 587 
4. Discussion 588 
Quantification of the magnitude of the immune response against HCMV has long been investigated 589 
as a method for predicting individuals better able to control viral replication in clinical settings. In the 590 
context of CMI this has centred on measuring the frequency of IFNy CD3+ T cells that recognise 591 
HCMV antigens, with the assumption that a direct correlation between frequency and control exists. 592 
In this study, we investigated CMI to HCMV in both SOT recipients and healthy controls. These in 593 
vitro CMI assays suggest that the use of IFNγ as a proxy for HCMV-specific control in vivo may not 594 
represent the best measure of the antiviral activity of immune cells from immune suppressed SOT 595 
recipients. Our view that measurement of IFNy is not a robust biomarker is supported by two pieces 596 
of evidence: firstly, a clear lack of correlation between CD3+ T cell IFNγ responses and DNAemia 597 
resolution in a small cohort of D+R- kidney transplant patients undergoing primary HCMV infection 598 
was observed. Secondly, no correlation between IFNγ production from HCMV peptide stimulated 599 
PBMC and the ability of these supernatants to inhibit virus dissemination was observed. Instead, we 600 
established that a fully autologous HCMV infection and immune cell co-culture system, 601 
incorporating both direct cell-cell and secreted antiviral immunity, was much more effective in 602 
distinguishing between HCMV-specific immunity in healthy seropositive and seronegative donors. 603 
Using this approach, we demonstrated potent antiviral activity of CD8+ T cells and correlated this 604 
with control of viraemia in D+R+ transplant recipients. 605 
An important aspect of our study was the increased choice of antigens used to stimulate PBMC. This 606 
allowed us to test whether the variable predictive power of IFNγ-focused CMI assays was due to the 607 
limited choice of HCMV antigens used for stimulation of T cells. Many commercial assays which 608 
enumerate IFNγ responses to HCMV (eg T.Track CMV and T.SPOT-CMV) focus on a narrow range 609 
of lytic antigens, such as IE1 and pp65. However a number of studies have now demonstrated that 610 
the CD4+ and CD8+ T cell responses to HCMV are broader than this, and that not all seropositive 611 
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donors will respond to IE1/pp65 (Jackson et al., 2014, 2017a; Sylwester et al., 2005). Some studies 612 
have suggested that serology alone may over-estimate the proportion of healthy individuals who are 613 
HCMV seropositive compared to testing for HCMV serostatus by Western blot (Sukdolak et al., 614 
2013). We do not believe that false-positive HCMV serology explains all cases of individuals who 615 
fail to make a detectable IFNγ response to pp65, as we and others have noted that serostatus cannot 616 
be accurately predicted by the CD4+ or CD8+ T cell response to a single ORF, but rather by the 617 
combination of detectable responses to several ORFs (Jackson et al., 2017b; Sylwester et al., 2005). 618 
By increasing the range of immunodominant peptides used for CD3+ T cell stimulation beyond that 619 
used in commercial assays, we could better enumerate IFNγ FluoroSpot responses in seven D+R- 620 
SOT recipients. Importantly, this approach still did not identify any obvious differences in the 621 
immune responses of these patients to provide an explanation for why some recipients had resolution 622 
of viraemia, and others recurrent viraemia despite a broad T cell response. We considered delayed 623 
immune reconstitution and immune suppression as factors in the occurrence and recurrence of 624 
viraemia, as HCMV-specific CMI is known to reconstitute more quickly in R+ than R- transplant 625 
recipients (Eid et al., 2010) and to reconstitute at different rates in different patients (Abate et al., 626 
2010). However, that does not seem to explain the differences between patients who did and did not 627 
control viraemia, as all patients mounted T cell responses similar in magnitude and breadth to those 628 
seen in healthy seropositive donors. Additionally, all patients received similar immunosuppressive 629 
regimes, suggesting other factors might explain the variable efficacy of their T cells. 630 
A major aim of this study was to develop a robust method to identify and assess antiviral CMI 631 
responses in vitro to empower our ongoing work aimed at understanding the key aspects of the 632 
immune response that provide protection in some, but not all, transplant patients. It is well 633 
established that HCMV-infected cell lysates or peptide stimulation can be used to generate IFNγ 634 
responses from PBMC and CD4/8+ T cells (e.g. (Chanouzas et al., 2018; Jackson et al., 2017b; 635 
Sinclair et al., 2004). However, it became clear that this form of stimulation did not always translate 636 
directly into effective control of viral replication in our assays. Furthermore, they again confirmed 637 
that antiviral activity did not correlate with ability of T cells to produce IFNy. An obvious 638 
interpretation is that other cytokines play an important role in the control of viral replication. It is 639 
interesting to note that anti-HCMV activity of monocyte derived macrophages has been observed and 640 
that this was not mediated by IFNγ nor primary IFN or IFN although the identity of the secreted 641 
factor responsible for the activity was not determined (Becker et al., 2018). Other studies have shown 642 
that even in the presence of IFNγ or IFN or IFN neutralising antibodies, HCMV infection can still 643 
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be controlled by lymphocytes in a non-cytotoxic manner, with granzymes implicated in control (Shan 644 
et al., 2020). A non-biased mass spectrometry-based approach is likely to be required to elucidate the 645 
key antiviral components of effective secretomes. Taken together we feel that an antiviral assay 646 
system based on stimulation of PBMC with HCMV antigens did not provide sufficient specificity 647 
and sensitivity as a viable technique to better measure effective CMI in the transplant setting. 648 
To address this, we developed a fully autologous co-culture system to determine anti-HCMV activity 649 
of PBMC and/or isolated lymphocyte subsets. Without the need to use individual cytokines as 650 
proxies for potential in vivo control we reasoned it could provide a much more direct measure of anti-651 
HCMV status of a transplant patient’s immune response. One important aspect of our approach is 652 
that these responses can be characterised in aggregate (PBMC) and studied at the individual 653 
lymphocyte population level (NK or CD8+ T cells). As such the approach could potentially inform us 654 
about the relative importance of individual lymphocyte subsets and the interplay between these (as 655 
seen when PBMC is utilized) in order to mediate effective antiviral responses. Whole PBMC include 656 
innate, adaptive and so-called ‘innately adaptive’ immune cells (Ferreira, 2013), which have both 657 
individual and potentially synergistic antiviral activity. The antiviral capabilities of PBMC would 658 
include directly cytotoxic effector function, and secretion of antiviral soluble factors. In addition, the 659 
use of a dual-colour fluorescent HCMV strain allows the differential quantification on whether 660 
control acts on virus spread or late viral gene expression, or both. As such, the inhibition of viral 661 
dissemination demonstrated by PBMC from healthy seronegatives at higher E:T ratios was to be 662 
expected, as innate immune cells are present. However, the antiviral activity is rapidly diluted, and 663 
this is consistent with a degree of innate cell-mediated (NK cell) control of HCMV spread in both 664 
HCMV seropositives and seronegatives that we tested. It was however interesting to observe that NK 665 
cells derived from HCMV seropositive donors were no better or worse at controlling HCMV and that 666 
individuals with NK cells with good or poor antiviral control could be observed in both groups. We 667 
have previously shown that HCMV-specific memory T cells are not present in HCMV seronegative 668 
PBMC (Jackson et al., 2017b; Sylwester et al., 2005), which also explains why antiviral activity of 669 
PBMC from seronegative donors dilutes rapidly. Consequently, it is not surprising that very clear 670 
differences in the antiviral activity of CD8+ T cells can be seen between HCMV seropositive and 671 
seronegative donors reflecting the fundamental difference in efficacy of primary and memory T cell 672 
responses. 673 
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Another major advantage of determining antiviral capacity in this viral dissemination co-culture 674 
system, is the use of a low passage strain of HCMV that expresses the full complement of immune 675 
evasion genes. As such viral derived antigens, both incoming from initial virus infection and 676 
produced de novo, are processed and presented in the correct temporal and immune evasion contexts.  677 
This being the case, it is clear that CD8+ T cells derived from seropositive donors are still able to 678 
exert antiviral effector function despite immunoevasins (eg US2,3,6,11) that interfere with MHC 679 
Class I processing and cell surface expression (Reddehase, 2002) (Wills et al., 2015). Indeed, this is 680 
consistent with HCMV being asymptomatic in healthy individuals due to effective immune control. 681 
What this may reflect is that incoming HCMV proteins are processed and presented for T cell 682 
recognition prior to the virus interfering with this process, as has been suggested for Epstein-Barr 683 
virus (Forrest et al., 2019). It should also be noted that the ability of some HCMV immunoevasins to 684 
prevent MHC class I processing and presentation is dependent on the genotype of the host (eg US2 685 
cannot bind HLA-B*07 and *27 as efficiently as HLA-A genotypes (Gewurz et al., 2001; Reddehase, 686 
2002); US11 degrades HLA-A but is less effective against HLA-B, with HLA-B*44:02 particularly 687 
resistant (Zimmermann et al., 2019)). Thus, the HLA genotype of the donor will contribute to the 688 
effectiveness of HCMV evasion of CD8+ T cell control.   689 
The nature of the responding HCMV specific T cells is also an important factor. It is recognized that 690 
CD8+ T cells with a high avidity for HCMV peptides would require far less stimulation with their 691 
cognate antigens than low avidity CD8+ T cells (Villacres et al., 2003), and have potent cytotoxity, 692 
IFNγ production and proliferation in response to HCMV antigen stimulation (Ogonek et al., 2017; 693 
Villacres et al., 2003). It has been shown that only a relatively small amount of cell surface MHC 694 
class I expression is required to trigger a cytotoxic T cell response to eg IE1 further supporting the 695 
hypothesis that even minimal MHC class I presentation (despite viral MHC class I immunoevasins) 696 
of HCMV antigens to seropositive donor CD8+ T cells is sufficient for a strong antiviral response to 697 
infected fibroblasts (Besold et al., 2009). High affinity identical or near-identical public TCR 698 
sequences arise convergently in unrelated individuals in response to HCMV infection, via antigen-699 
driven selection (Gras et al., 2009). These high-affinity TCRs are part of an evolving T cell response 700 
to HCMV antigens in seropositive donors during long term carriage and reactivation events (Schober 701 
et al., 2018). More broadly, these observations are again consistent with the concept that 702 
measurement of the quality of an immune response is more important than quantity. 703 
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During the process of establishing this assay, our studies suggest that there is considerable variability 704 
in the ability of different donors’ NK cells to control HCMV spread and late gene expression. 705 
Furthermore, the data also suggest that no statistically significant difference in the ability of NK cells 706 
isolated from seropositives and seronegatives to control HCMV dissemination is evident. This 707 
observation is supported by a previous publication studying an independent cohort of NK cell donors, 708 
using non-autologous indicator fibroblasts (Chen et al., 2016), and work by other groups showing 709 
that not all NK cell clones are equally effective at lysing HCMV-infected autologous fibroblasts 710 
(Carr et al., 2002). The ability of NK cells to inhibit late viral gene expression, compared to 711 
inhibition of virus spread, is also similar to results from Wu and colleagues, who observed reduced 712 
HCMV UL86 (major capsid protein) expression in NK-fibroblast co-cultures, even though IE antigen 713 
expression was seen in almost every cell (Wu et al., 2015). 714 
In this study, we did not explore the phenotypic characteristics of the NK cells present in each donor, 715 
but it has been shown that there are a number of different NK cell subsets within an individual, 716 
independently expressing activating and inhibitory receptors (Cooper et al., 2001). HCMV may 717 
further epigenetically reprogram and diversify NK cell function and receptor expression in some 718 
subsets (Lee et al., 2015; Schlums et al., 2015). LIR1+ and LIR1- NK cells have also been shown to 719 
have differential activity against HCMV strains in a viral dissemination assay, suggesting 720 
interactions with specific residues within UL18 (Chen et al., 2016). The differences in NK cell 721 
control between donors may also reflect a number of host factors (Patel et al., 2018), including 722 
NKG2C copy number (Muntasell et al., 2013), HLA/KIR genotype interactions (Hadaya et al., 723 
2008), other host genetic factors (Yu et al., 2018), age (Manser and Uhrberg, 2016), and underlying 724 
health conditions (Brunetta et al., 2010). For seropositives, it may also be influenced by the HCMV 725 
strain to which the donor has previously been exposed (Chen et al., 2016) and how long ago the 726 
donor was infected (Vieira Braga et al., 2015). HCMV also has a repertoire of immunoevasins which 727 
impair or reduce NK cell activation (De Pelsmaeker et al., 2018). It is likely that the balance between 728 
evasion of NK cell control by the virus and superior NK cell recognition by some donors due to host 729 
factors leads to the complex variation in control of virus spread and late gene expression seen in our 730 
healthy donor cohorts. Importantly, our assay system provides the framework to systematically 731 
investigate these different variables in future studies. 732 
In this study, we have defined a functional assay that measures HCMV cell-mediated immunity and 733 
established the baseline antiviral CMI of healthy HCMV seropositives and seronegatives. This assay 734 
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is highly tractable and will allow the systematic investigation of host and viral factors that influence 735 
the ability of clinically relevant patient populations to control (or not control) HCMV viraemia. 736 
Importantly, this assay relies on a measure of antiviral activity, not T cell activation. The implications 737 
of this are obvious: for example, individuals infected with multiple HCMV strains (e.g. D+R+ 738 
cohort) may control their own virus but not the infection with a new strain as effectively. Given that 739 
it is likely that the R+ individuals’ T cells would likely recognise conserved HCMV antigens from 740 
either strain we can now ask how this translates into the control of the replication of multiple strains 741 
of HCMV by combining this assay with the power of whole viral genome sequencing and HCMV 742 
BAC recombineering. It is anticipated that the integration of these approaches will shed new light on 743 
the immune parameters and mechanisms critical for the control of HCMV in vivo.  744 
  745 
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Table 1: Participant characteristics 746 
Donor N Study Experiment Age range HCMV serostatus 
Healthy 10 Local 
volunteers 
Assessment of 
antiviral activity of 
lysate/peptide 
stimulated 
supernatants in 
VDA 
Autologous VDA 
30-63 6 seropositive 
4 seronegative  
Healthy 11 ARIA Assessment of 
antiviral activity of 
lysate/peptide 
stimulated 
supernatants in 
VDA 
23-76 9 seropositive 
2 unknown 
Healthy 16 AQUARIA Autologous VDA 31-76 10 seropositive 
6 seronegative 
Kidney Tx 
(D+R-) 
7 AMC FluoroSpot 
analysis of IFNγ-
producing CD3+ T 
cells 
21-66 7 seronegative 
Kidney Tx 
(D+R+) 
4 Royal Free Autologous VDA 
FluoroSpot 
analysis of IFNγ-
29-54 4 seropositive 
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producing CD3+ T 
cells 
 747 
  748 
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 1105 
Figure 1 1106 
Analysis of longitudinal HCMV virus load and HCMV specific CD3+ T cell IFNγ responses of 1107 
D+R- Kidney transplant patients. 1108 
 Two example D+R- kidney transplant patients with primary HCMV infection, T cell responses (spot 1109 
forming units per 10^6 CD3+ T cells) were measured by IFNγ FluoroSpot (green triangles connected 1110 
by a solid line) to HCMV peptide pools covering pp65 and UL144, IE1 and IE2, pp71 and US3, and 1111 
gB, as well as a polyclonal T cell stimulation as a positive control (‘POS’). Virus load (copies/ml 1112 
blood) was measured by QNAT of HCMV DNA (pink hexagons connected by a dashed line). Cyan 1113 
lines show the mean magnitude of response (+/- standard error) of CD3+ T cell IFNγ responses seen 1114 
in healthy seropositive individuals in the same age decade as the transplant recipient for each peptide 1115 
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pool (Jackson et al., 2017b). Patient 365 is an example of a D+R- patient with resolution of 1116 
DNAemia following the emergence of detectable CD3+ IFNγ responses to four HCMV lytic peptide 1117 
pools. Patient 352, in contrast, had DNAemia which recurred several times, despite also developing 1118 
detectable HCMV specific CD3+ T cell IFNγ responses which are comparable in frequency to those 1119 
seen age-matched in healthy seropostives. 1120 
 1121 
Figure 2 1122 
Quantification of HCMV dissemination and antiviral effect of polyclonally stimulated T cells.  1123 
A Viral dissemination assay using a dual-fluorescently tagged HCMV strain (Merlin mCherry-P2A-1124 
UL36 [vICA], GFP-UL32 [pp150]). Following a low MOI (0.01) infection of indicator fibroblasts, 1125 
infected cells become mCherry+ as the virus enters the immediate-early life cycle, and later become 1126 
mCherry+ GFP+ as the virus enters the late life cycle. The percentage of cells infected can be 1127 
visualised by fluorescent microscopy and quantified by two colour flow cytometry.  1128 
B Kinetics of virus dissemination in HFFF cells. Virus dissemination has been quantified by 1129 
flowcytometry at various time points post infection based on mCherry+ GFP- cells and on mCherry+ 1130 
GFP+ cells. 1131 
C Analysis of antiviral activity of supernatant from anti-CD3/CD28 stimulated T cells in PBMC 1132 
(supernatant donor ARIA060). Fibroblasts were infected at 0.01 MOI and cocultured with dilutions 1133 
of supernatant, following 10 days of incubation fibroblasts were harvested and analysed for mCherry 1134 
and GFP expression by flow cytometry. 1135 
D Analysis of antiviral activity of supernatant from anti-CD3/CD28 stimulated T cells in PBMC 1136 
from 10 independent donors, diluted 1:4. Fibroblasts were infected at 0.01 MOI and cocultured with 1137 
dilutions of supernatant, following 9-11 days of incubation fibroblasts were harvested and analysed 1138 
for mCherry and GFP expression by flowcytometry.  1139 
 1140 
Figure 3 1141 
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Analysis of the antiviral activity of PBMC stimulated with HCMV-infected fibroblast lysates 1142 
and pools of HCMV synthetic peptides specific for pp65, UL144,Gb, IE1,IE2, pp71 and US3. 1143 
A Antiviral activity of supernatants derived from PBMC from three different donors stimulated with 1144 
HCMV infected or uninfected fibroblast lysates. PBMC were also stimulated with anti-CD3/CD28 1145 
antibodies to generate a positive control antiviral supernatant. Fibroblasts were infected at 0.01 MOI 1146 
and co-cultured with 1:4 dilution of supernatant, following 9-11 days of incubation fibroblasts were 1147 
harvested and analysed for mCherry and GFP expression by flowcytometry. Significance determined 1148 
was by one-tailed T test, p < 0.05.  1149 
B Antiviral activity of HCMV peptide pools covering pp65 and UL144, IE1 and IE2, pp71 and US3, 1150 
and gB, as well as a polyclonal anti-CD3/CD28 antibody T cell stimulation as a positive control on 1151 
five independent HCMV seropositive donors. Significance determined by one-tailed T test, p < 0.05.  1152 
 1153 
Figure 4 1154 
Analysis of HCMV specific IFNγ FluoroSpot responses and antiviral activity of HCMV peptide 1155 
stimulated supernatants with and without IFNγ depletion.  1156 
A IFNγ FluoroSpot responses to HCMV peptide pools covering pp65 and UL144, IE1 and IE2, pp71 1157 
and US3, and gB, as well as a polyclonal anti-CD3/CD28 antibody T cell stimulation as a positive 1158 
control of PBMC from donor CMV1801, calculated as spot-forming units (SFU) per 10^6 PBMC 1159 
(background corrected).  1160 
B IFNγ FluoroSpot responses to HCMV peptide pools covering pp65 and UL144, IE1 and IE2, pp71 1161 
and US3, and gB, as well as a polyclonal anti-CD3/CD28 antibody T cell stimulation as a positive 1162 
control of PBMC from donor CMV332, calculated as spot-forming units (SFU) per 10^6 PBMC 1163 
(background corrected). 1164 
C The IFNγ concentration of supernatants following peptide stimulation (black) or after IFNγ 1165 
depletion by anti-IFNγ-coated FluoroSpot (cyan), measured by ELISA. 1166 
D The effect of IFNγ depletion on the antiviral activity of PBMC from donor CMV1801 stimulated 1167 
with HCMV peptide pools for pp65/UL144, IE1 & 2 and pp71/US3 or anti-CD3/CD28 antibody. 1168 
Bars labelled ‘IFNγ deplete’ were harvested from anti-IFNγ antibody-coated FluoroSpot plates and 1169 
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added to a VDA in parallel with supernatants generated with the same stimulants and PBMC cell 1170 
number. Significance determined by one-tailed T test, p < 0.05. 1171 
 1172 
Figure 5 1173 
Antiviral activity of whole PBMC from HCMV seropositive and seronegative donors co-1174 
cultured with HCMV infected autologous fibroblasts. 1175 
Violin plots showing results from viral dissemination assays of PBMC co-cultured with HCMV 1176 
infected fibroblasts for 10-14 days over a range of E:T ratios, fibroblasts were harvested and analysed 1177 
for mCherry and GFP expression by flowcytometry. A Virus spread determined by mCherry+ 1178 
fibroblasts and B by mCherry+ GFP+ fibroblasts. Cyan points show the range of control at each E:T 1179 
for seropositive donors; magenta points are seronegative donors. Significance was determined by 1180 
one-tailed T test, p < 0.05.  1181 
 1182 
Figure 6 1183 
Antiviral activity of purified CD8+ T cells from HCMV seropositive and seronegative donors 1184 
cocultured with HCMV infected autologous fibroblasts. 1185 
Violin plots showing results from Viral dissemination assays of PBMC cocultured with HCMV 1186 
infected fibroblasts for 10-14 days over a range of E:T ratios, fibroblasts were harvested and analysed 1187 
for mCherry and GFP expression by flowcytometry. (A) Virus spread determined by mCherry+ 1188 
fibroblasts and (B) by mCherry+ GFP+ fibroblasts. Cyan points show the range of control at each 1189 
E:T for seropositive donors; magenta points are seronegative donors. Significance was determined by 1190 
one-tailed T test, p < 0.05.  1191 
 1192 
Figure 7  1193 
Antiviral activity of purified NK cells from HCMV seropositive and seronegative donors 1194 
cocultured with HCMV infected autologous fibroblasts. 1195 
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Violin plots showing results from Viral dissemination assays of PBMC cocultured with HCMV 1196 
infected fibroblasts for 10-14 days over a range of E:T ratios, fibroblasts were harvested and analysed 1197 
for mCherry and GFP expression by flowcytometry. (A) Virus spread determined by mCherry+ 1198 
fibroblasts and (B) by mCherry+ GFP+ fibroblasts. Cyan points show the range of control at each 1199 
E:T for seropositive donors; magenta points are seronegative donors. Significance was determined by 1200 
one-tailed T test, p < 0.05.  1201 
 1202 
Figure 8:  1203 
Antiviral activity of PBMC, CD8+ T cells and NK cells from HCMV seropositive and 1204 
seronegative donors and from non-viraemic D+R+ kidney transplant recipients co-cultured 1205 
with HCMV infected autologous fibroblasts. 1206 
Violin plots showing results from Viral dissemination assays of (A) PBMC, (B) CD8+ T cells, and 1207 
(C) NK cells. Cells were co-cultured with HCMV infected fibroblasts for 10-14 days over a range of 1208 
E:T ratios, fibroblasts were harvested and analysed for mCherry and GFP expression by 1209 
flowcytometry. Virus spread determined by mCherry+ fibroblasts and by mCherry+ GFP+ 1210 
fibroblasts. D+R+ kidney transplant recipients were tested in a VDA from samples collected 1211 
immediately pre-transplant (T1), at one-two months (T2) and three months post-transplant. At T3 1212 
(post-transplant), PBMC, CD8+ T cells and NK cells were not statistically significantly different from 1213 
healthy seropositives in their control of virus dissemination. Cyan points show the range of control at 1214 
each E:T for seropositive donors; magenta points are seronegative donors. Purple points are samples 1215 
taken immediately pre-transplant. Blue points are samples taken one-two months post-transplant. 1216 
Grey points are samples taken three months post-transplant. Significance was determined by one-1217 
tailed T test, p < 0.05.  1218 
